The New England journal of medicine, 2024-04, Vol.390 (14), p.1265-1276
- Wu, Yi-Long
- Dziadziuszko, Rafal
- Ahn, Jin Seok
- Barlesi, Fabrice
- Nishio, Makoto
- Lee, Dae Ho
- Lee, Jong-Seok
- Zhong, Wenzhao
- Horinouchi, Hidehito
- Mao, Weimin
- Hochmair, Maximilian
- de Marinis, Filippo
- Migliorino, M. Rita
- Bondarenko, Igor
- Lu, Shun
- Wang, Qun
- Ochi Lohmann, Tania
- Xu, Tingting
- Cardona, Andres
- Ruf, Thorsten
- Noe, Johannes
- Solomon, Benjamin J.
2024
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Wu, Yi-Long
- Dziadziuszko, Rafal
- Ahn, Jin Seok
- Barlesi, Fabrice
- Nishio, Makoto
- Lee, Dae Ho
- Lee, Jong-Seok
- Zhong, Wenzhao
- Horinouchi, Hidehito
- Mao, Weimin
- Hochmair, Maximilian
- de Marinis, Filippo
- Migliorino, M. Rita
- Bondarenko, Igor
- Lu, Shun
- Wang, Qun
- Ochi Lohmann, Tania
- Xu, Tingting
- Cardona, Andres
- Ruf, Thorsten
- Noe, Johannes
- Solomon, Benjamin J.
- Titel
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
- Ist Teil von
- The New England journal of medicine, 2024-04, Vol.390 (14), p.1265-1276
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2024
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- In a trial of adjuvant treatment for patients with resected ALK -positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib and 63.7% with standard chemotherapy.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2310532Titel-ID: cdi_proquest_miscellaneous_3037396282
- Format
- –
- Schlagworte
- Cancer therapies, Central nervous system, Chemotherapy, Committees, Critical Care, Critical Care General, Drug dosages, Drug withdrawal, Hematology, Immunotherapy, Kinases, Lung Cancer, Magnetic resonance imaging, Non-small cell lung carcinoma, Oncology, Platinum, Pulmonary, Safety, Small cell lung carcinoma, Statistical analysis, Thoracic surgery, Treatments in Oncology